BICO Group
ISIN: SE0013647385 | Ticker: BICO | LEI: 549300FE4PT8NDXXNK85
Country: Sweden
BICO (formerly CELLINK) is a leading life science tools company offering life science tools that enable human organ and tissue production. By converging different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology; so called Bio Convergence, we enable our customers to improve people's health and lives for the better.
With a focus on the ecosystems of bioprinting, multi-omics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to print human tissues, perform high-throughput drug screening and develop new diagnostics solutions.
We create the future of life-saving treatments.
BICO has more than 25,000 instruments in the field and is entrusted by more than 3,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 10,000 publications.
2016
Served areaWorldwide
HeadquartersLångfilsgatan 9, 41277 Gothenburg – Sweden
| Line item in (sek) | 01.09.2019 | 01.01.2021 | 01.01.2022 |
|---|---|---|---|
| Assets | N/A | 2,513,900,000.00 | 9,754,600,000.00 |
| Noncurrent Assets | N/A | 1,446,700,000.00 | 7,100,600,000.00 |
| Property Plant And Equipment | N/A | 52,500,000.00 | 209,100,000.00 |
| Noncurrent Receivables | N/A | 13,000,000.00 | 20,400,000.00 |
| Deferred Tax Assets | N/A | 39,500,000.00 | 96,500,000.00 |
| Longterm Deposits | N/A | 0.00 | 3,400,000.00 |
| Current Assets | N/A | 1,067,200,000.00 | 2,654,000,000.00 |
| Inventories | N/A | 85,300,000.00 | 353,500,000.00 |
| Current Trade Receivables | N/A | 176,400,000.00 | 576,900,000.00 |
| Current Prepayments | N/A | 2,300,000.00 | 19,100,000.00 |
| Other Current Receivables | N/A | 10,800,000.00 | 88,200,000.00 |
| Cash and cash equivalents | 39,800,000.00 | 434,900,000.00 | 481,200,000.00 |
| Equity And Liabilities | N/A | 2,513,900,000.00 | 9,754,600,000.00 |
| Equity | 549,600,000.00 | 2,208,500,000.00 | 6,802,700,000.00 |
| Issued Capital | N/A | 1,300,000.00 | 1,600,000.00 |
| Retained Earnings | N/A | -46,400,000.00 | -273,800,000.00 |
| Additional Paidin Capital | N/A | 2,299,500,000.00 | 7,017,100,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 2,201,900,000.00 | 6,773,900,000.00 |
| Noncontrolling Interests | N/A | 6,600,000.00 | 28,800,000.00 |
| Liabilities | N/A | 305,400,000.00 | 2,951,900,000.00 |
| Noncurrent Liabilities | N/A | 151,100,000.00 | 2,221,400,000.00 |
| Deferred Tax Liabilities | N/A | 59,600,000.00 | 260,200,000.00 |
| Other Noncurrent Liabilities | N/A | 0.00 | 393,200,000.00 |
| Longterm Borrowings | N/A | 26,700,000.00 | 1,350,300,000.00 |
| Current Liabilities | N/A | 154,300,000.00 | 730,500,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 33,000,000.00 | 129,100,000.00 |
| Current Contract Liabilities | N/A | 36,200,000.00 | 201,500,000.00 |
| Other Current Liabilities | N/A | 4,000,000.00 | 151,900,000.00 |
| Current Loans Received And Current Portion Of Noncurrent Loans Received | N/A | 2,000,000.00 | 5,000,000.00 |
| Line item in (sek) | 01.09.2019/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
|---|---|---|
| Revenue From Contracts With Customers | 416,000,000.00 | 1,257,300,000.00 |
| Other Income | 28,100,000.00 | 73,800,000.00 |
| Changes In Inventories Of Finished Goods And Work In Progress | -3,500,000.00 | -13,200,000.00 |
| Other Work Performed By Entity And Capitalised | 60,700,000.00 | 94,000,000.00 |
| Raw Materials And Consumables Used | 120,800,000.00 | 362,200,000.00 |
| Employee Benefits Expense | 230,800,000.00 | 669,800,000.00 |
| Depreciation And Amortisation Expense | 52,700,000.00 | 191,800,000.00 |
| Other Expense By Nature | 13,400,000.00 | 18,300,000.00 |
| Profit Loss From Operating Activities | -51,800,000.00 | -236,900,000.00 |
| Finance Income | 600,000.00 | 96,300,000.00 |
| Finance Costs | 2,900,000.00 | 72,800,000.00 |
| Profit Loss Before Tax | -54,100,000.00 | -213,400,000.00 |
| Income Tax Expense Continuing Operations | -5,200,000.00 | 15,800,000.00 |
| Profit (loss) | -48,900,000.00 | -229,200,000.00 |
| Profit Loss Attributable To Owners Of Parent | -48,100,000.00 | -227,600,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | -800,000.00 | -1,600,000.00 |
| Line item in (sek) | 01.09.2019 | 01.01.2021 | 01.01.2022 |
|---|---|---|---|
| Profit (loss) | N/A | -48,900,000.00 | -229,200,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -13,300,000.00 | 169,500,000.00 |
| Other Adjustments For Noncash Items | N/A | 64,700,000.00 | 173,700,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 900,000.00 | -21,500,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -79,300,000.00 | -409,200,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 417,500,000.00 | 3,540,200,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 30,100,000.00 | 110,900,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 103,800,000.00 | 156,100,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -828,000,000.00 | -4,453,800,000.00 |
| Proceeds From Issuing Shares | N/A | 1,336,300,000.00 | 3,609,500,000.00 |
| Proceeds From Issuing Other Equity Instruments | N/A | 11,700,000.00 | 0.00 |
| Payments Of Other Equity Instruments | N/A | 100,000.00 | 0.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 30,100,000.00 | 0.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 2,000,000.00 | 73,900,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 13,400,000.00 | 37,600,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 1,308,800,000.00 | 4,900,100,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 401,500,000.00 | 37,100,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -6,500,000.00 | 9,200,000.00 |
| Cash and cash equivalents | 39,800,000.00 | 434,900,000.00 | 481,200,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 15.11.23 | Jacob Thordenberg | Other | Buy | SEK 860,042.08 |
| 11.05.23 | Ulrika Dellby | Other | Buy | SEK 59,260.00 |
| 23.02.23 | Helena Skåntorp | Other | Buy | SEK 100,093.50 |
| 10.01.23 | Carsten Browall | Other | Sell | SEK 8,356,960.00 |
| 10.01.23 | Carsten Browall | Other | Other | SEK 5,947,200.00 |
| 10.01.23 | Carsten Browall | Other | Buy | SEK 5,947,200.00 |
| 10.11.22 | Bengt Sjöholm | Other | Buy | SEK 1,939,292.85 |
| 10.11.22 | Åsa Hillsten | Other | Sell | SEK 412,976.00 |
| 05.10.22 | Bengt Sjöholm | Other | Buy | SEK 1,563,500.00 |
| 28.09.22 | Rolf Classon | Other | Buy | SEK 839,100.00 |
SE0013647385
LEI549300FE4PT8NDXXNK85
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryLife Sciences Tools & Services
Sub-IndustryLife Sciences Tools & Services
Listed Stock ExchangeKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.